This study investigates advanced solid tumors with KRAS gene alteration. The purpose of this study is to understand more about these tumors and how they behave.
The study evaluates the safety and effectiveness of an investigational medication. Researchers will look at how the body processes the medication and its potential effects on tumors.
- Who can participate: Adults with advanced solid tumors with a KRAS gene alteration can join. Participants need to have a life expectancy of at least 3 months and meet other health criteria.
- Study details: Participants will take an investigational medication.